10 studies found for:    Congenital Myasthenia
Show Display Options
Rank Status Study
1 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
2 Completed Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Condition: Congenital Myasthenic Syndrome
Intervention: Drug: Albuterol
3 Available Expanded Access Study of Amifampridine Phosphate in LEMS, Congenital Myasthenic Syndrome, or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
4 Recruiting 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome
Interventions: Drug: 3,4-DIAMINOPYRIDINE;   Drug: 3,4-Diaminopyridine
5 Enrolling by invitation Ephedrine for the Treatment of Congenital Myasthenia
Condition: Myasthenic Syndromes, Congenital
Intervention: Drug: Ephedrine
6 Completed Pregnancy Outcomes in Congenital Myasthenie Syndrome
Condition: Congenital Myasthenic Syndrome
Intervention:
7 Available Treatment Use of 3,4-Diaminopyridine
Conditions: Lambert Eaton Myasthenic Syndrome (LEMS);   Myasthenic Syndromes, Congenital
Intervention: Drug: 3,4-diaminopyridine
8 No longer available Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Condition: Lambert Eaton Myasthenic Syndrome (LEMS)
Intervention: Drug: 3,4-diaminopyridine
9 Active, not recruiting Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Condition: Myasthenia Gravis
Intervention: Biological: Hematopoietic Stem Cell Transplantation
10 Enrolling by invitation Study of an Intervention to Improve Problem List Accuracy and Use
Conditions: Attention Deficit Disorder With Hyperactivity;   Asthma;   COPD;   Breast Cancer;   Coronary Artery Disease;   Congestive Heart Failure;   Diabetes;   Glaucoma;   Hemophilia;   Hypertension;   Hyperthyroidism;   Hypothyroidism;   Myasthenia Gravis;   Osteoporosis;   Osteopenia;   Renal Failure;   Renal Insufficiency;   Sickle Cell Disease;   Stroke
Intervention: Other: MAPLE

Indicates status has not been verified in more than two years